<b>Gapping up <br/>In reaction to strong earnings/guidance: </b>COST +0.9%<br/><br/><b>M&A news:</b> EZCH +13.8% (Mellanox to acquire EZCH (halted) for $25.50/share in cash; sees deal accretive to non-GAAP EPS on day one), WDC +10.3% (announces a $3.775 bln equity investment by Unisplendour; agrees to purchase Western Digital common stock at $92.50/share), AMCN +9% (enters into definitive merger agreement for going private transaction for $6.00 per American depositary share), PSEM +6.5% (Montage Technology Group has proposed to acquire PSEM for $18.50/share in cash, representing a competing bid to DIOD's prior $17.00 per share)<br/><br/><b>Select biotech/pharma related names showing strength</b>: NYMX +5.1%, CTIC +5%, ARIA +4.4%, SHPG +4%, MYL +3.3%, NVS +3.1%, ICPT +2.8%, SNY +2.8%, GSK +2.1%, BMY +1.4%<br/><br/><b>Select EU stocks trading higher: </b>CCL +3.4%, ALU +3.4%, AV +3.4%, NOK +3.3%, AEG +3%, UN +2.9%, ALV +2.8%, DEO +2.8%, ING +2.2%<br/><br/><b>Select energy names showing strength: </b>PBR +8.2%, SD +3.8%, STO +2.8%, BP +2.3%<br/>Other news: MDWD +25.8% (awarded a contract valued at up to $112 million), CMLS +17.4% (appoints new CEO), NVAX +7.3% (Announces Positive Top-Line Data From RSV F Vaccine Phase 1 Clinical Trial), RENT +7.2% (Rentrak will merge into a wholly-owned subsidiary of comScore in stock-for-stock merger; each share of Rentrak will be converted into the right to receive 1.15 shares of comScore), AAP +6.6% (Starboard Value takes a 3.7% stake, has met with mangement, believes shares could top $360, according to the WSJ), OXGN +6.4% (announced plans for the further advancement of its lead investigational drug, CA4P), RL +6.2% (President of Old Navy leaves Gap for Ralph Lauren), SCOR +6.1% (Rentrak will merge into a wholly-owned subsidiary of comScore in stock-for-stock merger; each share of Rentrak will be converted into the right to receive 1.15 shares of comScore), NRF +6.1% (authorizes the repurchase of up to $500 million of its outstanding common stock), BVXV +5.9% (receives regulatory clearance from the Hungarian Regulatory Authority and the Central Ethics Committee in Budapest to initiate a Phase IIb clinical trial for its Universal Flu Vaccine), STX +5.9% (in sympathy with WDC), FCAU +5.3% (CNBC reporting co's Ferrari offering likely to launch by Friday), SFUN +4.5% (still checking), SUNE +4.2% (cont strength), JKS +4% (announces a settlement in its securities class action), TAC +3.8% (announced elimination of 239 positions, primarily at its corporate head office in Calgary; expected to result in an additional cost-savings of ~$25 mln), CLVS +3.7% (announces FDA has accepted co's NDA for rociletinib and has granted it a priority review status with a PDUFA date of March 30, 2016; EMA has accepted co's MAA), UA +2.9% (still checking), F +2.7% (autonames rebounding in overseas trade), TSLA +2.4% (launches Model X SUV -- 'estimated delivery for new reservations is the latter half of 2016'), VOD +2.2% (Vodafone PLC and TPG Telecom Limited announced two commercial agreements, valued at more than $1 billion), TRIL +2.2% (announces update on CD47 program; completed the manufacture of clinical-grade drug product), TRAK +1.7% (DoJ announced it will require Cox Automotive to divest DealerTrak's automobile dealership full-featured inventory management solution (IMS) business in order for Cox to acquire Dealertrack)<br/><br/><b>Analyst comments:</b> ESPR +5.8% (upgraded to Neutral from Sell at Chardan Capital Markets), VRX +4.6% (initiated with a Buy at BofA/Merrill), HSBC +1.8% (upgraded to Buy from Neutral at UBS)<br/>Gapping down<br/>In reaction to disappointing earnings/guidance: CUDA -24.9%, EXXI -5.5%, ATU -3.2%, DMND -2.6%<br/><br/><b><br/>Other news:</b> DCI -8.6% (files to delay its 10-K citing ongoing investigation and potential financial statement misstatements), GPS -6.2% (President of Old Navy left co to become CEO of Ralph Lauren), USAT -4.3% (filed to delay Form 10-K following identification of deficiencies in both the design and operating effectiveness of the Company's internal control over financial reporting), SRPT -3.9% (announces USPTO Decision in Patent Interference Case with BioMarin (BMRN)), NBG -2.3% (cont vol in the stock)<br/><br/><b>Analyst comments</b>: GPC -1.1% (downgraded to Sell from Neutral at Goldman)<br/><br/>Briefing.com